Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: An 8-week, randomized, double-blind, placebo-controlled study-Reference-Cited by-同舟云学术

Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: An 8-week, randomized, double-blind, placebo-controlled study

Published:2005-06 Issue:6 Volume:27 Page:715-727
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Davidson Michael H.,Bays Harold,Rhyne James,Stein Evan,Rotenberg Keith,Doyle Ralph

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference28 articles.

1. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia;Adkins;Drugs,1997

2. Update on fenofibrate;Guay;Cardiovasc Drug Rev,2002

3. Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome;Davidson;Am J Cardiol,2004

4. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia;Balfour;Drugs,1990

5. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state;Genest;J Cardiovasc Pharmacol,2000

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Photosafety Assessment Strategy Based on the Photochemical and Pharmacokinetic Properties of Both Parent Chemicals and Metabolites;Drug Metabolism and Disposition;2015-08-21

2. A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations;Cardiology Research;2013

3. Influence of Cardiovascular Medication on Nutritional Status;Handbook of Drug-Nutrient Interactions;2009

4. Fenofibrate for Cardiovascular Disease Prevention in Metabolic Syndrome and Type 2 Diabetes Mellitus;The American Journal of Cardiology;2008-12

5. Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates;Acta Cardiologica;2008-04-01